adherium

ASX Release

Appendix 4C
Quarterly Cash Flow Report to 30 September 2025

Summary:

- Accelerated commercial growth with a 55% quarter-over-quarter increase in all channel device shipments, with 745 devices contributing to 2,161 devices shipped calendar year-to-date across all channels. Of these, 414 were Remote Patient Monitoring (RPM) devices shipped in the September 2025 quarter.
- Enhanced patient education call center launched in August driving significant step change in patient acquisition and engagement
- Groundbreaking iCARE study results demonstrate unprecedented adherence rates and validate Hailie® platform's value proposition for payers and health systems
- Major product platform enhancement with Hailie Care application
- Post end of the quarter, Adherium received a $287,000 payment from AstraZeneca in October
- Post the end of the quarter, Adherium has received $318,084 from shareholders exercising options under the Early Exercise Incentive Offer (ASX Announcement dated 10 October 2025)
- In addition, the Company has received commitments from its four largest shareholders to exercise options prior to 15 November 2025, along with other shareholders exercising their options, the Company is expecting to receive approximately $2.42 million.
- The Early Exercise Incentive Offer remains open for all option holders until 15 November 2025.

Melbourne, Australia – 31 October 2025: Leading digital health company Adherium Limited (ASX:ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, presents its Appendix 4C cash flow report for the quarter ended 30 September 2025.

Commercial Patient Growth - Step Change Acceleration

September 2025 quarter marked a transformational quarter for commercial execution, with the launch of the new patient education call center in August driving significant acceleration in patient acquisition and activation.

September 2025 Quarter Commercial Metrics:

- **Device Shipments:** 414 units shipped in September 2025 quarter, representing 55% quarter-over-quarter growth from 265 units in preceding quarter
- **September Momentum:** 201 shipments in September alone, a 112% increase over the average monthly shipments in preceding quarter
- **New Patient Activations:** 329 new patients activated in September quarter, up 59% compared to preceding quarter

- **Pipeline Growth:** Strong pipeline of shipped devices expected to convert to activated patients through next quarter, as typical activation lag is approximately 30 days

The patient education call center, launched in August 2025, has demonstrated steady improvement in conversion efficiency. The call center serves as a critical enabler for scaling patient acquisition across existing partnerships while creating a repeatable, efficient model for onboarding patients from new medical group partners.

Existing Partnership Performance

Allergy Partners: Continued steady growth in provider activation and patient enrollment within Allergy Partners' national network. The call center launch has accelerated patient onboarding efficiency, with further expansion expected in the coming quarter and beyond.
SENTA Partners: The Company continues to expand reach within SENTA, with ongoing efforts to activate additional large practices in the Southeastern United States.
AMC Health and Tenovi: Both RPM platform partners experienced continued growth in patient enrollment during September 2025 quarter, with strong adoption of the Hailie® Smartinhaler across their existing programs. These partnerships continue to demonstrate the versatility of the Hailie® platform across diverse care delivery models.
Intermountain Health iCARE Program: Following the September announcement of preliminary study results, the Intermountain Health partnership continues to evolve. The Company is working closely with Intermountain Health and CareCentra to leverage the study findings for expanded commercial arrangements and to support publication of comprehensive clinical data.
CIIC (Consortium of Independent Immunology Clinics): The strategic GPO partnership signed in March 2025 continues to drive practice awareness and engagement, with member practices gaining streamlined access to the Hailie® platform. This partnership creates an accelerated pathway for practice onboarding across 33 states.

Platform and Product Development - Hailie Care Launch

The Company made significant progress in September 2025 quarter toward the launch of the next-generation Hailie Care application and platform, designed to meet the evolving needs of the business and its customers as the patient base scales.

iCARE Study: Clinical Validation for Commercial Scale

On 15 September 2025, Adherium announced preliminary results from the groundbreaking iCARE study conducted in partnership with Intermountain Health and CareCentra. The study represents the largest real-world respiratory monitoring care program for COPD and asthma patients, involving 4,000 Hailie® Smartinhalers® supporting up to 2,500 patients across five Intermountain Health facilities over two years.

Key Clinical Outcomes:

- **Record Adherence:** Up to 235% increase in real-world adherence compared to published norms (20-40%), with average two-week baseline adherence of 62%
- **Gold Standard Achievement:** Approximately 40% of patients reached the critical threshold of >80% adherence, a level associated with 50% fewer respiratory exacerbations

- **Exceptional Persistence:** 54% of patients remained engaged for 12+ months, far exceeding typical digital health benchmarks of 30-45%
- **System-Level Impact:** Clinically meaningful reductions in inpatient admissions, 30-day readmissions, average length of stay, and lower reliance on rescue medications, resulting in decreased overall cost of care
- **High-Risk Population Success:** Strongest engagement observed in elderly, high-risk patients (ages 70-80), including those with depression—the highest-cost segment requiring the most hospitalizations

The data generated from nearly 1,000 patients creates a foundation for AI-driven predictive algorithms to anticipate exacerbations before they occur, strengthening Adherium's long-term value proposition to healthcare systems, payers, and population health programs.

Leadership and Strategic Direction

As announced on 22 July 2025, Dawn Bitz assumed the role of Chief Executive Officer, bringing nearly 30 years of transformational leadership experience in the global medical device and digital health industries. Under her leadership, the Company has accelerated its commercial execution, expanded its operational capabilities, and strengthened its strategic partnerships to drive sustainable growth in the US market.

Ms. Bitz's proven track record of scaling businesses from concept through global commercialisation, combined with her deep expertise in respiratory care and clinical innovation, positions Adherium to capitalise on the significant market opportunity in the US.

September 2025 Quarter Product Milestones:

- **Enhanced Observability:** Implemented comprehensive traceability and system alert capabilities across patient mobile apps, clinician dashboard, and core platform to monitor key patient actions and system health
- **Cybersecurity Strengthening:** Enhanced HIPAA and NIST Cybersecurity Framework controls to implement best practices and ensure enterprise-grade security as the platform scales
- **Beta Testing:** Successfully completed beta testing of the Hailie Care application with key provider stakeholders and patients, validating usability and functionality
- **November Launch:** Hailie Care application on track for early beta launch in November 2025, with full commercial rollout planned for early 2026

The Hailie Care platform represents a strategic investment in scalable infrastructure that will support:

- Improved patient engagement and retention through enhanced mobile experience
- Streamlined clinician workflows with better data visualisation and actionable insights
- AI-driven adherence optimisation and predictive analytics capabilities
- Seamless integration with EMR systems and health system platforms

This platform enhancement positions Adherium to deliver on the promise demonstrated in the iCARE study by turning data into action for patients and providers while enabling sustainable, value-based care models.

Capital Position

The Board continues to monitor Company sales performance and the timing of R&D refunds across both the Australian and New Zealand operations to inform future funding requirements.

Post quarter end, Adherium received $318,000 from the exercise of 64 million options under the Early Exercise Incentive Offer (ASX announcement 10 October 2025) and has secured commitments from its four largest shareholders to exercise a further 450 million options by 15 November 2025, expected to provide an additional $2.42 million in funding. An EMDG grant of $30,000 was received in October.

The Early Exercise Incentive Offer remains open for all option holders until 15 November 2025.

Outlook - December 2025 Quarter and Beyond

The Company enters December 2025 quarter with strong momentum across commercial, product, and clinical validation dimensions. Key priorities include:

Commercial Execution:

- Continue optimising call center performance to achieve sustained improvement in conversion rates
- Scale patient onboarding across existing partnerships (Allergy Partners, SENTA, AMC Health, Tenovi)
- Drive adoption of AIRSUPRA and Breztri Aerosphere compatible Smartinhalers

Product and Platform:

- Complete Hailie Care application beta launch in November 2025
- Continue enhancing observability, cybersecurity, and EMR integration capabilities
- Prepare for full commercial rollout of Hailie Care platform in early 2026

Clinical Evidence and Commercialisation:

- Work with Intermountain Health and CareCentra to publish comprehensive iCARE study results
- Leverage iCARE clinical validation for payer engagement and value-based care contracting

Summary of recent announcements up to this date:

- Appointment of Dawn Bitz as Chief Executive Officer (22 July 2025)
- New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma (15 September 2025)

Other components of cash flow

- Cash on hand at the end of the quarter was $52,000 compared to $43,000 in the preceding quarter
- Receipts from customers for the quarter was $134,000, compared to $146,000 in the previous quarter. This quarters receipts from remote patient monitoring subscriptions was $118,000, compared to $17,000 in the previous quarter. Notably, $287,000 was received from AstraZeneca in October
- Payment for R&D activities were $35,000 compared to $23,000 in the preceding quarter
- Advertising, platform integration, sales and marketing payments were $978,000, compared to the prior quarter of $671,000
- Staff and contractor payments were $1,712,000 in the September quarter compared to $1,410,000 in the June quarter
- During the quarter, administration and corporate payments was $1,752,000 compared to $591,000 in the preceding quarter, reflecting the timing of scheduled payments incurred during the current period
- Related party payments of $54,000 in the quarter to 30 September 2025 were for payment of Directors' fees

For more information about Adherium and its revolutionary respiratory solutions, please visit adherium.com.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries
investors@adherium.com

Media Enquiries:
Haley Chartres
H^CK
Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at **adherium.com**

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Adherium Limited

ABN	**Quarter ended ("current quarter")**
24 605 352 510	30 September 2025

Consolidated statement of cash flows			**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**			
1.1	Receipts from customers		134	134
1.2	Payments for			
	(a)	research and development	(35)	(35)
	(b)	product manufacturing and operating costs	(150)	(150)
	(c)	advertising and marketing	(978)	(978)
	(d)	staff costs	(1,712)	(1,712)
	(e)	administration and corporate costs	(1,752)	(1,752)
1.3	Dividends received (see note 3)		-	-
1.4	Interest received		7	7
1.5	Interest and other costs of finance paid		(2)	(2)
1.6	Income taxes paid		-	-
1.7	Government grants and tax incentives		-	-
1.8	Other (provide details if material)		-	-
1.9	**Net cash from / (used in) operating activities**		**(4,488)**	**(4,488)**

2.	**Cash flows from investing activities**			
2.1	Payments to acquire or for:			
	(a)	entities	-	-
	(b)	businesses	-	-
	(c)	property, plant and equipment	(21)	(21)
	(d)	investments	-	-
	(e)	intellectual property	-	-
	(f)	other non-current assets	-	-

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(21)**	**(21)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,492	4.492
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(318)	(318)
3.5	Proceeds from borrowings	350	350
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**4,524**	**4,524**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	43	43
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,488)	(4,488)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(21)	(21)

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
4.4	Net cash from / (used in) financing activities (item 3.10 above)	4,524	4,524
4.5	Effect of movement in exchange rates on cash held	(6)	(6)
4.6	**Cash and cash equivalents at end of period**	**52**	**52**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	47	32
5.2	Call deposits	5	11
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**52**	**43**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	54
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	4,842	4,842
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	4,842	4,842
7.5	**Unused financing facilities available at quarter end**		-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Nil

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(4,488)
8.2	Cash and cash equivalents at quarter end (item 4.6)	52
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	52
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.01

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Yes

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Adherium remains confident it will continue to raise sufficient capital to fund its operation, having received $287,000 for the Arrival Study, a $30,000 EMDG grant, and $318,084 from option exercised post quarter end, with a further $2.42 million expected from committed shareholder option conversions.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Please refer to 8.62.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

31 October 2025

Date: ....

By the board

Authorised by: ....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.